SGCB and heart failure: The results of the SOCRATES-REDUCED study, however, highlight thechallenges in moving the concept of modulating sGC and thereby addressing therelative cGMP deficit forward.10 In SOCRATES-REDUCED, a phase 2 dose-finding study inpatients with heart failure with reduced ejection fraction and worsening chronicHF, the oral sGC stimulator vericiguat did not meet its primary endpoint ofreducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) at 12 weeks whenall doses were combined, but was well tolerated.